On a corporate action affecting ordinary shares of Allakos Inc. (ALLK)

On April 2, 2025, Allakos Inc. entered into a merger agreement under which it will be acquired by Concentra Biosciences, LLC. Allakos Inc. stockholders will receive $0.33 in cash for each share of Allakos Inc. that they own. Transaction is expected to close in May 2025. For more details, please, refer to the company’s website.   

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.